[go: up one dir, main page]

PE20010211A1 - Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina - Google Patents

Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina

Info

Publication number
PE20010211A1
PE20010211A1 PE2000000553A PE0005532000A PE20010211A1 PE 20010211 A1 PE20010211 A1 PE 20010211A1 PE 2000000553 A PE2000000553 A PE 2000000553A PE 0005532000 A PE0005532000 A PE 0005532000A PE 20010211 A1 PE20010211 A1 PE 20010211A1
Authority
PE
Peru
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Application number
PE2000000553A
Other languages
English (en)
Inventor
Steven Lee Bender
Shao Song Chu
Larry Andrew Alegria
Suzanne Pritchett Benedict
Allen J Borchardt
Robert Steve Kania
Mitchell David Nambu
Anna Maria Tempczyk-Russell
Sepehr Sarshar
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of PE20010211A1 publication Critical patent/PE20010211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE COMPUESTOS DE DIAMINOTIAZOL DE FORMULA I, DONDE: R1 ES ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILO, HETEROARILO OPCIONALMENTE SUSTITUIDO CON R6-CO, R6-CS; R6 ES ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ALQUENILO, ARILO, HETEROARILO, NR7R8; R7 Y R8 SON H, ALQUILO, ARILO, HETEROARILO; R2 ES HIDROXI, HALO, CIANO, NITRO, ALQUILO, ALQUENILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILO, HETEROARILO, -C=O-Ra, Ra ES H, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILO, HETEROARILO, -C(O)-O-Ra-; DONDE Ra ES H, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILO, HETEROARILO, -C(O)-NRcRb, Rb Y Rc SON H, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILO, ENTRE OTROS; X ES C, N; Q ES UN RADICAL DIVALENTE DE 2-3 DE C, N, O, S, C-R5, N-R5, R5 ES OH, HALO, CIANO, AMINO, ALQUILO, ARILO, HETEROARILO, ALCOXI, QUE JUNTO A C* Y N* FORMAN UN ANILLO DE 6 MIEMBROS AROMATICO O NO AROMATICO. LOS COMPUESTOS I SON MODULADORES O INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR DE QUINASA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DEL CANCER, TUMOR, PROLIFERACION CELULAR
PE2000000553A 1999-06-04 2000-06-02 Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina PE20010211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13781099P 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
PE20010211A1 true PE20010211A1 (es) 2001-03-16

Family

ID=22479135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000553A PE20010211A1 (es) 1999-06-04 2000-06-02 Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina

Country Status (34)

Country Link
US (1) US6620828B2 (es)
EP (1) EP1181283B1 (es)
JP (1) JP2003501420A (es)
KR (1) KR20020015333A (es)
CN (1) CN1359380A (es)
AP (1) AP2001002341A0 (es)
AT (1) ATE288424T1 (es)
AU (1) AU778071B2 (es)
BG (1) BG106276A (es)
BR (1) BR0011585A (es)
CA (1) CA2371158A1 (es)
CZ (1) CZ20014213A3 (es)
DE (1) DE60017894T2 (es)
EA (1) EA200101268A1 (es)
EE (1) EE200100659A (es)
ES (1) ES2234628T3 (es)
HR (1) HRP20020008A2 (es)
HU (1) HUP0202897A3 (es)
IL (1) IL146094A0 (es)
IS (1) IS6183A (es)
MA (1) MA25530A1 (es)
MX (1) MXPA01012483A (es)
NO (1) NO20015045L (es)
NZ (1) NZ514881A (es)
OA (1) OA11959A (es)
PE (1) PE20010211A1 (es)
PL (1) PL352714A1 (es)
SK (1) SK17302001A3 (es)
SV (1) SV2002000096A (es)
UA (1) UA71971C2 (es)
UY (1) UY26190A1 (es)
WO (1) WO2000075120A1 (es)
YU (1) YU85601A (es)
ZA (1) ZA200108291B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GEP20032896B (en) * 1997-10-27 2003-02-25 Agouron Pharma 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
BR0009721A (pt) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2005504014A (ja) * 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
NZ538490A (en) 2002-08-02 2006-12-22 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-kit inhibitors
NZ540381A (en) * 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
MXPA05008878A (es) * 2003-02-21 2005-10-05 Pfizer Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
HUE047569T2 (hu) 2003-04-11 2020-04-28 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
EP1618133A1 (en) * 2003-04-17 2006-01-25 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
WO2005007091A2 (en) * 2003-07-07 2005-01-27 Georgetown University Histone deacetylase inhibitors and methods of use thereof
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
RS50521B (sr) * 2004-01-12 2010-05-07 Applied Research Systems Ars Holding N.V. Derivati tiazola i njihova upotreba
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JP2008505971A (ja) * 2004-07-12 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素阻害剤
UA96735C2 (en) * 2005-05-24 2011-12-12 Мерк Сероно Са Thiazole derivatives and use thereof
EP1885716B1 (en) 2005-05-24 2012-11-07 Merck Serono SA Thiazole derivatives and use thereof
PL2404919T3 (pl) 2005-11-08 2014-01-31 Vertex Pharma Związek heterocykliczny użyteczny jako modulator transporterów zawierających kasetę wiążącą ATP
AU2006336504C9 (en) * 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
AU2012244242B2 (en) * 2005-12-28 2015-05-21 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
KR20080091369A (ko) * 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물
JP5369257B2 (ja) * 2006-02-15 2013-12-18 アッヴィ・インコーポレイテッド 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用
CN101384568B (zh) * 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
US9289398B2 (en) 2006-03-30 2016-03-22 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
EP2041116A1 (de) 2006-07-07 2009-04-01 Boehringer Ingelheim International GmbH Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008141119A2 (en) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
US20100240657A1 (en) * 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2693473A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
KR20160040745A (ko) 2007-12-07 2016-04-14 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
WO2009076140A1 (en) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
ES2528032T3 (es) 2009-01-16 2015-02-03 Rigel Pharmaceuticals, Inc. Inhibidores de Axl para su uso en terapia de combinación para prevenir, tratar o manejar cáncer metastásico
EP2492269A4 (en) * 2009-10-19 2013-08-07 Taisho Pharmaceutical Co Ltd aminothiazole
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
EP4005559B1 (en) 2010-04-07 2025-02-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
RU2644723C2 (ru) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
EP2842955B1 (en) * 2012-04-26 2016-10-05 ONO Pharmaceutical Co., Ltd. Trk-inhibiting compound
ES2853485T3 (es) 2013-02-19 2021-09-16 Ono Pharmaceutical Co Derivado de urea como compuesto inhibidor de Trk
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
CN106455571A (zh) 2014-03-06 2017-02-22 Ptc医疗公司 1,2,4‑噁二唑苯甲酸的药物组合物和盐
HRP20211194T1 (hr) 2014-11-18 2021-10-29 Vertex Pharmaceuticals Inc. Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
WO2017075312A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
US11001564B2 (en) * 2016-09-13 2021-05-11 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途
WO2025007859A1 (en) * 2023-07-03 2025-01-09 Insilico Medicine Ip Limited Substituted thiazole compounds as cdk2/4/6 inhibitors and methods of use thereof
CN116874442B (zh) * 2023-07-27 2025-10-24 武汉呈瑞生物医药科技有限公司 一种有机化合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en) 1981-05-27 1987-01-22 Labatt Brewing Co. Ltd. Malt sterilisation with hydrogen peroxide
EP0218728A1 (en) 1985-04-03 1987-04-22 Yamanouchi Pharmaceutical Co. Ltd. Phenylene derivatives
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
WO1993019052A1 (en) 1992-03-24 1993-09-30 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
WO1996023783A1 (en) 1995-02-02 1996-08-08 Smithkline Beecham Plc Indole derivatives as 5-ht receptor antagonist
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
ATE211740T1 (de) 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
JP3554337B2 (ja) 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
GEP20032896B (en) * 1997-10-27 2003-02-25 Agouron Pharma 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
AU754184B2 (en) 1997-11-04 2002-11-07 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
CZ20001621A3 (cs) 1997-11-04 2001-08-15 Pfizer Products Inc. Bioisoterické nahrazení katecholu indazolem v terapeuticky aktivních sloučeninách
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
KR100705142B1 (ko) 1998-09-29 2007-04-06 와이어쓰 홀딩스 코포레이션 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린

Also Published As

Publication number Publication date
PL352714A1 (en) 2003-09-08
EA200101268A1 (ru) 2002-06-27
BG106276A (bg) 2002-10-31
KR20020015333A (ko) 2002-02-27
NO20015045D0 (no) 2001-10-17
NZ514881A (en) 2003-10-31
AU5725400A (en) 2000-12-28
AU778071B2 (en) 2004-11-11
AP2001002341A0 (en) 2001-12-31
SV2002000096A (es) 2002-06-07
IS6183A (is) 2001-11-29
ZA200108291B (en) 2002-12-24
IL146094A0 (en) 2002-07-25
WO2000075120A1 (en) 2000-12-14
MXPA01012483A (es) 2002-07-30
HRP20020008A2 (en) 2004-02-29
MA25530A1 (fr) 2002-10-01
ES2234628T3 (es) 2005-07-01
SK17302001A3 (sk) 2004-01-08
EP1181283A1 (en) 2002-02-27
OA11959A (en) 2006-04-17
US6620828B2 (en) 2003-09-16
US20020025976A1 (en) 2002-02-28
YU85601A (sh) 2004-09-03
DE60017894T2 (de) 2005-12-29
JP2003501420A (ja) 2003-01-14
EE200100659A (et) 2003-02-17
HUP0202897A2 (hu) 2002-12-28
CN1359380A (zh) 2002-07-17
UY26190A1 (es) 2000-12-29
CA2371158A1 (en) 2000-12-14
BR0011585A (pt) 2002-03-19
EP1181283B1 (en) 2005-02-02
UA71971C2 (en) 2005-01-17
NO20015045L (no) 2002-02-04
CZ20014213A3 (cs) 2002-04-17
DE60017894D1 (de) 2005-03-10
HUP0202897A3 (en) 2004-12-28
ATE288424T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
GT200000107A (es) Procedimiento para la obtencion de "compuestos de indazol y composiciones farmaceuticas para inhibir las quinasas deproteina y metodos para su uso".
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
AR017588A1 (es) Compuestos de benzotiazol, inhibidores de la proteina tirosina quinasa, metodo para tratar desordenes asociados con dicha proteina, y las composicionesfarmaceuticas que contienen dichos compuestos
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
ES2171884T3 (es) Compuestos de quinazolina.
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
PE20070790A1 (es) Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
AR007969A1 (es) Compuestos derivados de pirroles sustituidos, su utilizacion y composiciones farmaceuticas que contienen tales compuestos
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed